KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.

Item
http://www.wikidata.org/entity/Q34748747
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancerKRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.Circulating Cell-Free Tumour DNA in the Management of Cancer.Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathwayEffectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis.Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approachThe prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.Prognostic value of carcinoembryonic antigen level in patients with colorectal cancer liver metastasis treated with percutaneous microwave ablation under ultrasound guidance.Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.
P2860

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.

Item
http://www.wikidata.org/entity/Q34748747
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@ast
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@en
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@nl
type
label
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@ast
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@en
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@nl
prefLabel
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@ast
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@en
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
KRAS mutations in tumor tissue ...... metastatic colorectal cancer.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932